Expressed specifically in malignant pool in ovarian cancer tumor fluid; overexpressed in aromatase inhibitor resistant estrogen receptor-positive (ER+) breast cancer; upregulated in head and neck cancer cell lines; downregulated in chronic myelogenous leukemia stem cells. This evidence concerns the gene CYP19A1 and neoplasm.